Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

Digestive diseases and sciences - 1 Jun 2023

Bonkovsky Herbert L, Rudnick Sean P, Ma Christopher D, Overbey Jessica R, Wang Kelly, Faust Denise, Hallberg Csilla, Hedstrom Karli, Naik Hetanshi, Moghe Akshata, Anderson Karl E

Abstract excerpt

BACKGROUND AND AIMS: Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether ledipasvir/sofosbuvir is effective for treating both PCT and CHC, we treated patients with CHC + PCT solely with ledipasvir/sofosbuvir and followed them for at least 1 year to assess cure of CHC and remission of PCT. METHODS: Between September 2017 and May 2020, 15 of 23 screened PCT + CHC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorenes

Share to Hepatitis C, Chronic

Share to Porphyria Cutanea Tarda

Share to Porphyrins

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 36811718
DOI: 10.1007/s10620-023-07859-8
PMCID: PMC9945827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.PMID 36811718Read ↗

Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.Semantic proximity Read ↗

Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.Semantic proximity Read ↗

Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension studySemantic proximity Read ↗

Porphyria cutanea tarda in Scotland: underlying associations and treatment approaches.Semantic proximity Read ↗

Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.Semantic proximity Read ↗

Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report.Semantic proximity Read ↗

Porphyria Cutanea Tarda and Patterns of Long-term Sick Leave and Disability Pension: a 24-year Nationwide Matched Cohort StudySemantic proximity Read ↗

Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.Semantic proximity Read ↗

Porphyria Cutanea TardaSemantic proximity Read ↗

Iron, genes, and viruses: the porphyria cutanea tarda triple threat.Semantic proximity Read ↗

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.